JP7688578B2 - メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 - Google Patents

メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 Download PDF

Info

Publication number
JP7688578B2
JP7688578B2 JP2021532487A JP2021532487A JP7688578B2 JP 7688578 B2 JP7688578 B2 JP 7688578B2 JP 2021532487 A JP2021532487 A JP 2021532487A JP 2021532487 A JP2021532487 A JP 2021532487A JP 7688578 B2 JP7688578 B2 JP 7688578B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
heterocyclyl
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021532487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512156A (ja
JP2022512156A5 (https=
Inventor
アラム ムザファル
クリアリー リア
フルーリー メリッサ
ペイ チョンホア
スティール リチャード
サットン ジェイムズ
イー．ノックス ジョン
イー．アール．ニュービー ザカリー
Original Assignee
アイディアヤ バイオサイエンシーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイディアヤ バイオサイエンシーズ，インコーポレイティド filed Critical アイディアヤ バイオサイエンシーズ，インコーポレイティド
Publication of JP2022512156A publication Critical patent/JP2022512156A/ja
Publication of JP2022512156A5 publication Critical patent/JP2022512156A5/ja
Priority to JP2025086518A priority Critical patent/JP2025116052A/ja
Application granted granted Critical
Publication of JP7688578B2 publication Critical patent/JP7688578B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021532487A 2018-12-10 2019-12-09 メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 Active JP7688578B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025086518A JP2025116052A (ja) 2018-12-10 2025-05-23 メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862777715P 2018-12-10 2018-12-10
US62/777,715 2018-12-10
US201962835853P 2019-04-18 2019-04-18
US62/835,853 2019-04-18
US201962883945P 2019-08-07 2019-08-07
US62/883,945 2019-08-07
PCT/US2019/065260 WO2020123395A1 (en) 2018-12-10 2019-12-09 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025086518A Division JP2025116052A (ja) 2018-12-10 2025-05-23 メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体

Publications (3)

Publication Number Publication Date
JP2022512156A JP2022512156A (ja) 2022-02-02
JP2022512156A5 JP2022512156A5 (https=) 2022-12-16
JP7688578B2 true JP7688578B2 (ja) 2025-06-04

Family

ID=69138003

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532487A Active JP7688578B2 (ja) 2018-12-10 2019-12-09 メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体
JP2025086518A Pending JP2025116052A (ja) 2018-12-10 2025-05-23 メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025086518A Pending JP2025116052A (ja) 2018-12-10 2025-05-23 メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体

Country Status (17)

Country Link
US (4) US12503467B2 (https=)
EP (1) EP3894396A1 (https=)
JP (2) JP7688578B2 (https=)
KR (1) KR20210103498A (https=)
CN (2) CN119528824A (https=)
AU (1) AU2019395338B2 (https=)
BR (1) BR112021010842A2 (https=)
CA (1) CA3121236A1 (https=)
CL (1) CL2021001508A1 (https=)
CO (1) CO2021008895A2 (https=)
IL (1) IL283743A (https=)
MA (1) MA54452A (https=)
MX (1) MX2021006841A (https=)
PH (1) PH12021551274A1 (https=)
SG (1) SG11202105469YA (https=)
TW (1) TWI863945B (https=)
WO (1) WO2020123395A1 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123395A1 (en) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
JP7736700B2 (ja) * 2020-02-28 2025-09-09 リミックス セラピューティクス インコーポレイテッド 複素環アミド及びスプライシングを調節するためのその使用
US20240208965A1 (en) * 2020-06-10 2024-06-27 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
IL297879A (en) * 2020-06-22 2023-01-01 Hoffmann La Roche Amidopyrimidone derivatives
KR20230026479A (ko) 2020-06-22 2023-02-24 에프. 호프만-라 로슈 아게 설폰 유도체
CN116406271B (zh) * 2020-07-14 2024-09-24 南京再明医药有限公司 双环类化合物
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
WO2022063128A1 (zh) * 2020-09-24 2022-03-31 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
CA3201663A1 (en) 2020-11-20 2022-05-27 Amgen Inc. Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione
JP2023553492A (ja) * 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
US20240124454A1 (en) 2020-12-31 2024-04-18 Nanjing Zaiming Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2022222911A1 (zh) * 2021-04-19 2022-10-27 武汉人福创新药物研发中心有限公司 嘧啶酮化合物及其用途
JP2024516429A (ja) * 2021-04-30 2024-04-15 サイノハブ ファーマシューティカル カンパニー リミテッド メチオニンアデノシルトランスフェラーゼ阻害剤、その調製方法およびその適用
WO2022256808A1 (en) * 2021-06-02 2022-12-08 Ideaya Biosciences Inc. Combination therapy comprising a mat2a inhibitor and type i prmt inhibitor
EP4347569A4 (en) * 2021-06-02 2025-03-26 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
CN117412967A (zh) * 2021-06-02 2024-01-16 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
AR127404A1 (es) * 2021-10-20 2024-01-17 Insilico Medicine Ip Ltd Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
US20250090533A1 (en) * 2021-11-12 2025-03-20 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a taxane
CN118414338A (zh) * 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
JP2025503186A (ja) * 2022-01-26 2025-01-30 勤浩医▲葯▼（▲蘇▼州）有限公司 Ｍｔａｐ欠失型がん治療用メチオニンアデノシルトランスフェラーゼ２ａ阻害剤
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
WO2023185811A1 (zh) 2022-03-29 2023-10-05 首药控股(北京)股份有限公司 一种新型杂环化合物
GB202204913D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd antiviral therapy
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
JP2025521737A (ja) 2022-06-27 2025-07-10 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 三環式化合物およびその使用
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
AU2023361063A1 (en) 2022-10-13 2025-04-17 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
TW202440126A (zh) 2022-11-30 2024-10-16 美商安進公司 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療
JP2025540086A (ja) * 2022-11-30 2025-12-11 アイディアヤ バイオサイエンシーズ，インコーポレイティド ２－オキソキナゾリン結晶形態
EP4626887A1 (en) * 2022-11-30 2025-10-08 Ideaya Biosciences, Inc. Atropisomers of mat2a inhibitors
WO2024118943A2 (en) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor
CN116425751B (zh) * 2022-12-19 2024-01-23 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物
WO2024217502A1 (en) * 2023-04-19 2024-10-24 Insilico Medicine Ip Limited Methionine adenosyltransferase 2a (mat2a) inhibitor combinations and uses thereof
KR20250174628A (ko) * 2023-04-19 2025-12-12 인실리코 메디신 아이피 리미티드 결정성 메티오닌 아데노실트랜스퍼라제 2a (MAT2A) 억제제 및 이의 용도
CN116283800B (zh) * 2023-05-16 2023-07-18 英矽智能科技(上海)有限公司 氧代喹唑啉类化合物及其应用
CN121586715A (zh) * 2023-06-14 2026-02-27 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法
CN116478172B (zh) * 2023-06-20 2023-09-05 英矽智能科技(上海)有限公司 吡咯并[3,2-d]嘧啶类化合物及其应用
WO2025059579A1 (en) 2023-09-15 2025-03-20 Ideaya Biosciences, Inc. Methods of treating mat2a related diseases
WO2025064750A1 (en) 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Combination therapy with a parg inhibitor
WO2025072544A1 (en) 2023-09-27 2025-04-03 Ideaya Biosciences, Inc. Sulfonamino indazole compounds as inhibitors of parg
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166274A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025223561A1 (zh) * 2024-04-26 2025-10-30 中国科学院上海药物研究所 一种喹唑啉酮并五元杂环化合物及其药用组合物和用途
WO2025250569A1 (en) 2024-05-29 2025-12-04 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors
CN118724899B (zh) * 2024-07-03 2025-09-30 中国药科大学 2(1h)-喹喔啉酮化合物、其药物组合物及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
WO2018045071A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020113071A1 (en) 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3202661A (en) 1962-11-27 1965-08-24 Hoffmann La Roche Substituted 3-amino 4-phenyl quinolones
US4096144A (en) 1970-12-08 1978-06-20 Sumitomo Chemical Company, Limited Process for preparing quinazolinone derivatives and their 2-(N-mono-substituted amino)-phenyl ketone intermediate derivatives
JPS5761758B2 (https=) 1974-01-11 1982-12-25 Hisamitsu Pharmaceutical Co
WO1994007498A1 (fr) 1992-10-07 1994-04-14 Sumitomo Pharmaceuticals Company, Limited Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale
EP0759454B1 (en) 1994-05-11 2002-03-06 Asahi Kasei Kabushiki Kaisha para-ORIENTED AROMATIC POLYAMIDE MOLDING AND PROCESS FOR PRODUCING THE SAME
US5525711A (en) * 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
NZ322197A (en) 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
TW504504B (en) 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
AU742452B2 (en) 1997-08-28 2002-01-03 Bristol-Myers Squibb Company 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
WO2004065542A2 (en) 2002-12-30 2004-08-05 Exelixis, Inc. MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US7049309B2 (en) 2003-10-14 2006-05-23 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one potassium channel modulators
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
RU2477046C2 (ru) 2006-11-22 2013-03-10 Сумитомо Кемикал Компани, Лимитед Агент для ингибирования сигнальной функции цитокинина
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
EP2266984A1 (en) 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
PT2611797T (pt) * 2010-08-31 2017-02-07 Hanmi Science Co Ltd Derivados de quinolina ou de quinazolina com atividade indutora de apoptose nas células
CN110015962B (zh) 2011-01-28 2022-03-15 肯塔基大学研究基金会 茋类似物和治疗癌症的方法
JP2014519340A (ja) 2011-06-16 2014-08-14 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． バイオマーカー組成物および方法
CN103842364A (zh) 2011-09-30 2014-06-04 奇尼塔公司 抗病毒化合物
CN104011050A (zh) * 2011-12-22 2014-08-27 霍夫曼-拉罗奇有限公司 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物
CN102816197B (zh) 2012-08-24 2015-04-29 四川大学华西医院 一种新的嘧啶并嘧啶类核苷类似物、制备方法及其形成的超分子结构和应用
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
KR102470130B1 (ko) 2016-07-18 2022-11-24 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 아폽토시스 억제제
WO2018039772A1 (en) 2016-09-02 2018-03-08 FutureVault Inc. Real-time document filtering systems and methods
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11161839B2 (en) * 2017-05-26 2021-11-02 The Institute Of Cancer Research: Royal Cancer Hospital 2-quinolone derived inhibitors of BCL6
WO2018221433A1 (ja) 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
US11524960B2 (en) 2018-03-30 2022-12-13 Servier Pharmaceuticals Llc Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
GB2575490A (en) 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
US11376256B2 (en) 2018-07-19 2022-07-05 Agency For Science, Technology And Research Method of treating a methionine-dependent cancer
WO2020123395A1 (en) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
LT3902803T (lt) 2018-12-27 2023-04-25 Les Laboratoires Servier Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui
EA202191800A1 (ru) 2018-12-27 2021-09-13 Ле Лаборатуар Сервье Сас Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
US20240208965A1 (en) 2020-06-10 2024-06-27 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2021252680A1 (en) 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
EP4165040B1 (en) 2020-06-10 2025-08-27 Ideaya Biosciences, Inc. 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors
US20230227409A1 (en) 2020-06-10 2023-07-20 Ideaya Biosciences, Inc. Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
TW202227082A (zh) 2020-08-12 2022-07-16 美商施維雅製藥有限公司 用於治療癌症之組合療法
WO2022053908A1 (ja) 2020-09-11 2022-03-17 株式会社半導体エネルギー研究所 表示装置、表示モジュール、及び電子機器
EP4347569A4 (en) 2021-06-02 2025-03-26 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
US20250090533A1 (en) 2021-11-12 2025-03-20 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a taxane
WO2023196985A1 (en) 2022-04-08 2023-10-12 Ideaya Biosciences, Inc. Methionine adenosyltransferase 2a inhibitors
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4626887A1 (en) 2022-11-30 2025-10-08 Ideaya Biosciences, Inc. Atropisomers of mat2a inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
WO2018045071A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020113071A1 (en) 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer

Also Published As

Publication number Publication date
AU2019395338A1 (en) 2021-07-29
MA54452A (fr) 2022-03-16
PH12021551274A1 (en) 2021-12-06
KR20210103498A (ko) 2021-08-23
MX2021006841A (es) 2021-07-02
TWI863945B (zh) 2024-12-01
US20220106276A1 (en) 2022-04-07
BR112021010842A2 (pt) 2021-08-24
CN119528824A (zh) 2025-02-28
CL2021001508A1 (es) 2022-01-21
US11130759B1 (en) 2021-09-28
US12503467B2 (en) 2025-12-23
JP2025116052A (ja) 2025-08-07
CO2021008895A2 (es) 2021-07-30
CN113166078A (zh) 2021-07-23
AU2019395338B2 (en) 2025-11-13
WO2020123395A1 (en) 2020-06-18
CA3121236A1 (en) 2020-06-18
US11084798B1 (en) 2021-08-10
CN113166078B (zh) 2024-11-19
JP2022512156A (ja) 2022-02-02
EP3894396A1 (en) 2021-10-20
US11046691B1 (en) 2021-06-29
SG11202105469YA (en) 2021-06-29
TW202039487A (zh) 2020-11-01
IL283743A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
JP7688578B2 (ja) メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体
JP6666263B2 (ja) グルタミナーゼの新規阻害剤
EP2651899B1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
JP5406039B2 (ja) タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
JP6783230B2 (ja) ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
CA2742007C (en) Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
JP2022058912A (ja) 特定の化学的実体、組成物、および方法
CN113563309B (zh) 吡啶类衍生物及其制备方法和用途
JP2010524962A (ja) オーロラキナーゼ阻害剤のための創薬法
TW201838981A (zh) 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
JP2017526720A (ja) キナーゼ阻害剤としての化合物および組成物
TW202214603A (zh) 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用
JP2022505872A (ja) アデノシン受容体アンタゴニストとしての５－アザインダゾール誘導体
RU2830169C2 (ru) Производные 2-оксохиназолина как ингибиторы метионин аденозилтрансферазы 2a

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250523

R150 Certificate of patent or registration of utility model

Ref document number: 7688578

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150